Disease · MONDO_0008364
Raynaud disease
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Raynaud disease. Diseases, record MONDO_0008364. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008364
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Raynaud syndrome, Raynaud's disease, Raynaud's disease (disorder), Raynaud's syndrome, Raynaud's syndrome (disorder), Raynaud's syndrome (disorder) [ambiguous], Raynaud's syndrome NOS (disorder), secondary Raynaud disease, secondary Raynaud phenomenon, secondary Raynaud's disease, secondary Raynaud's phenomenon
- Open Targets
Drugs9
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ONABOTULINUMTOXINA | CHEMBL1201574 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| TADALAFIL | CHEMBL779 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AMLODIPINE | CHEMBL1491 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SILDENAFIL | CHEMBL192 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| UDENAFIL | CHEMBL2103849 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VARDENAFIL | CHEMBL1520 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PF-00489791 | CHEMBL4210847 | Small molecule | Phase 2 | TTD | 1 | 0 | 0 | Drugs and targets |
| NITROGLYCERIN | CHEMBL730 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TREPROSTINIL | CHEMBL1237119 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets10
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | 5 | Phosphodiesterase 5A inhibitor | Phase 3 | https://conductscience.org/library/genes/8654 | Drugs and targets |
| CACNA1C | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2/3 | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2/3 | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1F | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2/3 | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1S | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2/3 | https://conductscience.org/library/genes/779 | Drugs and targets |
| GUCY1A1 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 1 | https://conductscience.org/library/genes/2982 | Drugs and targets |
| GUCY1A2 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 1 | https://conductscience.org/library/genes/2977 | Drugs and targets |
| GUCY1B1 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 1 | https://conductscience.org/library/genes/2983 | Drugs and targets |
| PTGIR | Prostacyclin receptor | 1 | Prostanoid IP receptor agonist | Early phase 1 | https://conductscience.org/library/genes/5739 | Drugs and targets |
| SNAP25 | Synaptosomal-associated protein 25 | 1 | Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | Phase 3 | https://conductscience.org/library/genes/6616 | Drugs and targets |
Trials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02165111 | Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome | Phase 3 | 40 | 2016-12-22 | Scleroderma, Raynaud's Syndrome | ONABOTULINUMTOXINA | Its record names the disease | ClinicalTrials.gov |
| NCT01280266 | Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon | Phase 2/3 | 29 | 2012-12-11 | Raynaud Phenomenon | AMLODIPINE, UDENAFIL | Its record names the disease | ClinicalTrials.gov |
| NCT01117298 | A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma | Phase 3 | 66 | Raynaud's Phenomenon, Digital Ulcers, Scleroderma | TADALAFIL | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01291199 | Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome | Phase 2/3 | 57 | Raynaud Syndrome | VARDENAFIL | Its record names the disease | ClinicalTrials.gov | |
| NCT02050360 | "As Required" Oral Sildenafil in Raynaud's Phenomenon | Phase 2/3 | 41 | Raynaud's Phenomenon | SILDENAFIL | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov | |
| NCT02583789 | Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon | Early phase 1 | 12 | Raynaud's Phenomenon | TREPROSTINIL | Its record names the disease | ClinicalTrials.gov | |
| NCT00700518 | Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon | Phase 1 | 10 | Raynaud's Phenomenon | NITROGLYCERIN | Open Targets' reading of its record | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Onabotulinumtoxin A vs Placebo: serious adverse events | 0 of 40 | 0 of 40 | 80 | NCT02165111 | Trial comparisons |
| Amlodipine vs Udenafil: serious adverse events | 0 of 26 | 2 of 26 | 52 | NCT01280266 | Trial comparisons |
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0008364
GET https://conductscience.org/api/diseases/v1/MONDO_0008364/drugs